What amount sold does Esculon, Inc. report in Form D filings?

The latest linked filings report $2.9M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Esculon, Inc.'s most recent SEC filing?

Esculon, Inc.'s most recent Form D filing was on 2017-11-27.

How many investors does Esculon, Inc. have?

The most recent Form D filing lists 14 investor(s).

What type of securities does Esculon, Inc. offer?

Esculon, Inc.'s SEC Form D filings indicate equity offerings.

Esculon, Inc.

CIK: 0001709643·Biotechnology·OMAHA, NE·Corporation·Founded 2016

Reported Sold

$2,925,826

Total Filings

Identified Offerings

Last Filed

Nov 27, 2017

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Nov 27, 2017Form D/A — Amendment

Reported sold: $2,925,826 · Target: $2,925,826

Rule 506(b)·14 investors

Changed: Reported amount sold, Offering target

Jun 19, 2017Form D — New notice

Reported sold: $969,680 · Target: $1,500,000

Rule 506(b)·14 investors

Jun 19, 2017Form D/A — Amendment

Reported sold: $1,554,984 · Target: $2,524,664

Rule 506(b)·14 investors

Changed: Reported amount sold, Offering target

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

67%

Latest reported sold across 1 identified offering

$2,925,826

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

ALAN CHESLER

Related Person

Appears on 3 filings

Evan Luxon

Related Person

Appears on 3 filings

Carter Meyer

Related Person

Appears on 3 filings

Danial Burnett

Related Person

Appears on 3 filings

Deepak Gangahar

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 27, 2017	Amendment	$2,925,826	$2,925,826	14
Jun 19, 2017	New	$1,500,000	$969,680	14
Jun 19, 2017	Amendment	$2,524,664	$1,554,984	14

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Accufy Diagnostics, Inc.

Biotechnology

Offering target: $2,000,000

Filed Oct 28, 2026